力生制药(002393) - 2020 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2020 was ¥332,679,628.71, a decrease of 23.43% compared to ¥434,462,480.17 in the same period last year[9] - Net profit attributable to shareholders was ¥34,252,525.69, down 22.90% from ¥44,426,621.86 year-on-year[9] - Operating revenue for the first quarter was CNY 332,679,628.71, a decrease of 23.43% year-on-year, primarily due to the impact of the COVID-19 pandemic and the "4+7" centralized procurement policy[19] - Net profit attributable to shareholders was CNY 34,252,525.69, down 22.90% compared to the same period last year, influenced by reduced hospital visits for non-emergency patients and lower drug prices[20] - Operating profit for the period was CNY 36,092,879.40, a decrease of 31.52% year-on-year, mainly due to reduced revenue[14] - Total operating revenue for Q1 2020 was CNY 332,679,628.71, a decrease of 23.4% compared to CNY 434,462,480.17 in Q1 2019[40] - Net profit for Q1 2020 was CNY 40,671,488.45, compared to CNY 52,558,312.26 in Q1 2019, reflecting a decrease of 22.6%[41] - The operating profit for Q1 2020 was CNY 45.40 million, a decline of 16.5% from CNY 54.38 million in Q1 2019[44] Cash Flow - The net cash flow from operating activities increased by 71.99% to ¥86,913,363.60, compared to ¥50,535,196.57 in the previous year[9] - Cash flow from operating activities increased by 71.99% year-on-year to CNY 86,913,363.60, attributed to decreased cash outflows from operating activities[20] - Cash and cash equivalents increased by 64.44% year-on-year to CNY 68,640,998.25, driven by the net cash flow from operating activities[14] - The net cash flow from operating activities increased to ¥67,895,733.15, up from ¥36,416,619.29 in the previous period, representing an increase of approximately 86.5%[51] - Total cash inflow from operating activities was ¥160,541,282.15, compared to ¥172,028,815.96 in the previous period, showing a decrease of about 6.5%[51] - Cash outflow from operating activities decreased to ¥92,645,549.00 from ¥135,612,196.67, a reduction of approximately 31.6%[51] Assets and Liabilities - Total assets at the end of the reporting period were ¥5,283,753,002.12, a slight increase of 0.21% from ¥5,272,702,523.46 at the end of the previous year[9] - Total assets as of March 31, 2020, amounted to CNY 5,283,753,002.12, slightly up from CNY 5,272,702,523.46 at the end of 2019[35] - Total liabilities decreased to CNY 834,112,867.19 from CNY 855,854,757.03 at the end of 2019, indicating a reduction of 2.4%[35] - The company reported a total asset value of ¥5,272,702,523.46, with total liabilities amounting to ¥855,854,757.03[57] - The total liabilities and owner's equity combined also amounted to approximately 3.56 billion, consistent with total assets[61] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 19,326[13] - The largest shareholder, Tianjin Jinhao Pharmaceutical Co., Ltd., holds 51.36% of the shares, totaling 93,710,608 shares[13] - The company did not engage in any repurchase transactions among the top 10 shareholders during the reporting period[14] Research and Development - The company's R&D expenses for the period were ¥20,248,379.12, a decrease of 46.73% compared to the previous year, primarily due to reduced spending on consistency evaluation[17] - Research and development expenses for Q1 2020 were CNY 20,248,379.12, down 46.8% from CNY 38,012,990.53 in Q1 2019[41] - The company reported a significant decrease in R&D investment, with expenses for Q1 2020 at CNY 10.16 million, compared to CNY 26.77 million in the previous year[44] Other Financial Metrics - Other income for the period was CNY 4,649,374.82, a significant increase of 2508.21% year-on-year, mainly due to government subsidies received[14] - Cash paid for purchasing goods and services was CNY 20,848,006.61, a decrease of 55.76% year-on-year, primarily due to an increase in acceptance bill payments[14] - Cash paid for fixed assets and other long-term assets was CNY 18,051,883.41, an increase of 125.41% year-on-year, as the company made payments for construction projects[21] - The company reported a decrease in sales expenses to CNY 30.40 million from CNY 53.91 million, reflecting cost-cutting measures[44] - The financial income for Q1 2020 included interest income of CNY 5.96 million, compared to CNY 2.09 million in the same period last year[44] Future Considerations - The company has implemented new revenue and leasing standards, which may affect future financial reporting[62] - The company has not yet audited the first quarter report, indicating that the figures may be subject to change[62]